ST Hulubao released its 2026 interim report, showing first-half operating revenue of 241 million yuan, down 52.6 percent year on year, and a loss of 113 million yuan, swinging from profit to loss compared with the same period last year. Net loss attributable to the parent after deducting non-recurring items was 119 million yuan, widening from 18.78 million yuan in the same period last year. Net operating cash flow was 44.49 million yuan, up 214.4 percent year on year. In the second quarter, operating revenue was 94.74 million yuan, down 44.5 percent year on year, and net loss attributable to the parent was 84.43 million yuan, widening from 21.94 million yuan in the same period last year. As of the end of the second quarter, total assets were 2.419 billion yuan, down 7.1 percent from the end of the previous year, and net assets attributable to the parent were 299 million yuan, down 27.5 percent from the end of the previous year. The company said its main business has not undergone any major changes, and it continues to focus on the research, development, production and sales of pediatric medicines, holding 359 drug approval numbers, of which 130 are products currently in production and on sale, and 118 are included in the national medical insurance catalogue.
Hainan Huluwa Pharmaceutical Group Co LtdFirst-half loss of 113 million yuan, swinging from profit to loss, with revenue down 52.6%.
